World journal of urology

publication venue for

SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer. 2018
Diagnosis and management of incidental ureterocele during the treatment of clinically localized prostate cancer. 2000
Safety and efficacy of GreenLight PVP in octogenarians: evaluation of the Global GreenLight Group database.. 41. 2023
Characterization of the histological response to the Butterfly Prostatic Retraction Device in patients with benign prostatic hyperplasia.. 41. 2023
Functional outcomes of GreenLight 180-W photoselective vaporization in patients with large (≥ 80 cc) prostates: an analysis of over 3000 men in the Global Greenlight Group (GGG) database.. 41. 2022
Prostatic artery embolization compared to transurethral resection of the prostate and prostatic urethral lift: a real-world population-based study.. 41. 2022
Development of a North American coordinated registry network for surgical treatment of benign prostatic hyperplasia.. 40. 2022
Functional and surgical outcomes of Aquablation in elderly men.. 40. 2022
GreenLight photovaporization of the prostate in high-medical-risk patients: an analysis of the Global GreenLight Group (GGG) database.. 40. 2022
Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive squamous bladder cancer: an international multi-centre collaboration.. 40. 2022
Natural history of lower urinary tract symptoms among men undergoing stereotactic body radiation therapy for prostate cancer with and without a Rectal Hydrogel Spacer.. 40. 2022
Carboplatin-based adjuvant chemotherapy versus observation after radical cystectomy in patients with pN1-3 urothelial bladder cancer.. 40. 2022
Real-world data comparing minimally invasive surgeries for benign prostatic hyperplasia.. 40. 2022
Plasmacytoid variant urothelial carcinoma of the bladder: effect of radical cystectomy and chemotherapy in non-metastatic and metastatic patients.. 40. 2022
Active surveillance for prostate cancer: comparison between incidental tumors vs. tumors diagnosed at prostate biopsies.. 40. 2021
Selection and evaluation of preoperative systemic inflammatory response biomarkers model prior to cytoreductive nephrectomy using a machine-learning approach.. 40. 2021
The impact of race/ethnicity on upstaging and/or upgrading rates among intermediate risk prostate cancer patients treated with radical prostatectomy.. 40. 2021
Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer.. 39. 2021
Safety and efficacy of TURP vs. laser prostatectomy for the treatment of benign prostatic hyperplasia in multi-morbid and elderly individuals aged ≥ 75.. 39. 2021
Risk factors associated with positive surgical margins' location at radical cystectomy and their impact on bladder cancer survival.. 39. 2021
Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer.. 39. 2021
Oncologic impact of delaying radical prostatectomy in men with intermediate- and high-risk prostate cancer: a systematic review.. 39. 2021
Role of systemic immune-inflammation index in patients treated with salvage radical prostatectomy.. 39. 2021
Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities.. 39. 2021
Frailty as predictor of complications in patients undergoing percutaneous nephrolithotomy (PCNL).. 39. 2021
Association of patients' sex with treatment outcomes after intravesical bacillus Calmette-Guérin immunotherapy for T1G3/HG bladder cancer.. 39. 2021
Predictive value of De Ritis ratio in metastatic renal cell carcinoma treated with tyrosine-kinase inhibitors.. 39. 2021
Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer.. 39. 2021
Real-world comparative effectiveness of shockwave lithotripsy versus ureterorenoscopy for the treatment of urinary stones.. 39. 2020
Association of De Ritis ratio with oncological outcomes in patients with non-muscle invasive bladder cancer (NMIBC).. 39. 2020
Adjuvant chemotherapy is ineffective in patients with bladder cancer and variant histology treated with radical cystectomy with curative intent.. 39. 2020
An evaluation of the federal adverse events reporting system data on adverse effects of 5-alpha reductase inhibitors.. 39. 2020
The association between plant-based content in diet and testosterone levels in US adults.. 39. 2020
Radical cystectomy plus chemotherapy in patients with pure squamous cell bladder carcinoma: a population-based study.. 39. 2020
The impact of treatment modality on survival in patients with clinical node-positive bladder cancer: results from a multicenter collaboration.. 39. 2020
Comparison of survival outcomes in patients with metastatic papillary vs. clear-cell renal cell carcinoma: a propensity-score analysis.. 39. 2020
Correction to: Unintended consequences of decreased PSA-based prostate cancer screening.. 38. 2020
Survival of contemporary patients with non-metastatic urachal vs. non-urachal adenocarcinoma of the urinary bladder.. 38. 2020
Expression of urokinase-type plasminogen activator system in non-metastatic prostate cancer.. 38. 2019
Dependence of laser-induced tissue ablation on optical fiber movements for laser prostatectomy.. 38. 2019
Complication rate after cystectomy following pelvic radiotherapy: an international, multicenter, retrospective series of 682 cases.. 38. 2019
Evaluation of the prognostic role of co-morbidities on disease outcome in renal cell carcinoma patients.. 38. 2019
Contemporary North-American population-based validation of the International Germ Cell Consensus Classification for metastatic germ cell tumors of the testis.. 38. 2019
Can men with lower urinary tract symptoms (LUTs) predict voided volumes?. 38. 2019
Conditional survival of patients with stage I-III squamous cell carcinoma of the penis: temporal changes in cancer-specific mortality.. 38. 2019
Association of super-extended lymphadenectomy at radical cystectomy with perioperative complications and re-hospitalization.. 38. 2019
Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor.. 38. 2019
Prognostic implications of prostatic urethral involvement in non-muscle-invasive bladder cancer.. 37. 2019
Propensity-matched analysis of patient-reported outcomes for neoadjuvant chemotherapy prior to radical cystectomy.. 37. 2019
Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study.. 37. 2019
Impact of intravesical therapy for non-muscle invasive bladder cancer on the accuracy of urine cytology.. 37. 2019
Complications and functional outcomes of high-risk patient with cardiovascular disease on antithrombotic medication treated with the 532-nm-laser photo-vaporization Greenlight XPS-180 W for benign prostate hyperplasia.. 37. 2018
Development and external validation of a pathological nodal staging score for patients with clear cell renal cell carcinoma.. 37. 2018
Regional differences in total hospital charges between open and robotically assisted radical prostatectomy in the United States.. 37. 2018
Survival effect of perioperative systemic chemotherapy on overall mortality in locally advanced and/or positive regional lymph node non-metastatic urothelial carcinoma of the upper urinary tract.. 37. 2018
The effect of androgen deprivation treatment on subsequent risk of bladder cancer diagnosis in male patients treated for prostate cancer.. 37. 2018
Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy.. 36. 2018
Unintended consequences of decreased PSA-based prostate cancer screening.. 37. 2018
An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer.. 37. 2018
Cost analysis of prostate cancer detection including the prostate health index (phi).. 37. 2018
Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy.. 37. 2018
Salvage topical therapy for upper tract urothelial carcinoma.. 36. 2018
Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought.. 36. 2018
Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer.. 36. 2018
Contemporary rates of adherence to international guidelines for pelvic lymph node dissection in radical cystectomy: a population-based study.. 36. 2018
Role of quantitative computed tomography texture analysis in the prediction of adherent perinephric fat.. 36. 2018
The impact of time to catheter removal on short-, intermediate- and long-term urinary continence after radical prostatectomy.. 36. 2018
Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer.. 36. 2018
Surgical treatment for clinical node-positive bladder cancer patients treated with radical cystectomy without neoadjuvant chemotherapy.. 36. 2018
Accuracy and prognostic value of variant histology and lymphovascular invasion at transurethral resection of bladder.. 36. 2017
Radical prostatectomy or radiotherapy reduce prostate cancer mortality in elderly patients: a population-based propensity score adjusted analysis.. 36. 2017
Effect of pathological high-risk features on cancer-specific mortality in non-metastatic clear cell renal cell carcinoma: a tool for optimizing patient selection for adjuvant therapy.. 36. 2017
Marital status and gender affect stage, tumor grade, treatment type and cancer specific mortality in T_1-2 N₀ M₀ renal cell carcinoma.. 35. 2017
Prognostic significance of Fuhrman grade and age for cancer-specific and overall survival in patients with papillary renal cell carcinoma: results of an international multi-institutional study on 2189 patients.. 35. 2017
Minimally invasive vs open nephrectomy in the modern era: does approach matter?. 35. 2017
Trends of lymphadenectomy in upper tract urothelial carcinoma (UTUC) patients treated with radical nephroureterectomy.. 35. 2017
Multicenter international experience of 532 nm-laser photo-vaporization with Greenlight XPS in men with large prostates (prostate volume > 100 cc).. 35. 2017
The impact of socioeconomic status on perioperative complications and oncologic outcomes in patients undergoing radical cystectomy.. 35. 2016
Prognostic role of expression of N-cadherin in patients with upper tract urothelial carcinoma: a multi-institutional study.. 35. 2016
Contemporary treatment patterns and outcomes of sarcomatoid bladder cancer.. 35. 2016
Androgen receptor expression is associated with adverse pathological features in ureteral but not in pelvicalyceal urothelial carcinomas of the upper urinary tract.. 35. 2016
Second-line treatment for metastatic clear cell renal cell cancer: experts' consensus algorithms.. 35. 2016
Impact of tumor histology and grade on treatment success of percutaneous renal cryoablation.. 35. 2016
A proposal of a new nomogram for predicting upstaging in contemporary D'Amico low-risk prostate cancer patients.. 35. 2016
HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC).. 35. 2016
Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy.. 35. 2016
Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study.. 35. 2016
Obstructive sleep apnea and Fuhrman grade in patients with clear cell renal cell carcinoma treated surgically.. 35. 2016
Second primary malignancies in renal cortical neoplasms: an updated evaluation from a single institution.. 34. 2016
Comparison of oncologic outcomes between sarcomatoid and clear cell renal cell carcinoma.. 34. 2016
Impact of smoking status on survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.. 34. 2016
Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent.. 34. 2015
Low yield of surveillance imaging after surgery for T1 kidney cancer.. 34. 2015
Multiparametric MRI of the prostate at 3 T: limited value of 3D (1)H-MR spectroscopy as a fourth parameter.. 34. 2015
Construct, content and face validity of the camera handling trainer (CHT): a new E-BLUS training task for 30° laparoscope navigation skills.. 34. 2015
Histologic subtype impacts cancer-specific survival in patients with sarcomatoid-variant renal cell carcinoma treated surgically.. 34. 2015
Molecular profile of urothelial carcinoma of the upper urinary tract: are pelvicalyceal and ureteral tumors different?. 34. 2015
Partial nephrectomy for renal tumors in solitary kidneys: postoperative renal function dynamics.. 33. 2015
TALL score for prediction of oncological outcomes after radical nephroureterectomy for high-grade upper tract urothelial carcinoma.. 33. 2015
Optimizing outcome reporting after radical cystectomy for organ-confined urothelial carcinoma of the bladder using oncological trifecta and pentafecta.. 33. 2015
Partial nephrectomy driven by cavitron ultrasonic surgical aspirator under zero ischemia: a pilot study.. 33. 2015
Comparison of the prognostic value of pretreatment measurements of systemic inflammatory response in patients undergoing curative resection of clear cell renal cell carcinoma.. 33. 2015
Histopathology and prognosis of de novo bladder tumors following solid organ transplantation.. 33. 2015
The impact of the AB0 and the Rhesus blood group system on outcomes in bladder cancer patients treated with radical cystectomy.. 33. 2015
Multicenter evaluation of the role of UroVysion FISH assay in surveillance of patients with bladder cancer: does FISH positivity anticipate recurrence?. 33. 2014
Postoperative complications and short-term oncological outcomes of patients aged ≥80 years undergoing robot-assisted radical cystectomy.. 33. 2014
Multi-institutional validation of the prognostic value of Ki-67 labeling index in patients treated with radical prostatectomy.. 33. 2014
Insignificant disease among men with intermediate-risk prostate cancer.. 32. 2014
Interobserver variability of R.E.N.A.L., PADUA, and centrality index nephrometry score systems.. 33. 2014
Prognostic value of prior history of urothelial carcinoma of the bladder in patients with upper urinary tract urothelial carcinoma: results from a retrospective multicenter study.. 33. 2014
Impact of warm versus cold ischemia on renal function following partial nephrectomy.. 33. 2014
Lower urinary tract symptoms in patients with liver cirrhosis.. 33. 2014
Management, pathology and outcomes of Bosniak category IIF and III cystic renal lesions.. 33. 2014
Diagnosis of renal tumors by in vivo proton magnetic resonance spectroscopy.. 33. 2014
Aurora A Kinase as a diagnostic urinary marker for urothelial bladder cancer.. 33. 2014
Single-Incision Transumbilical Surgery (SITUS) versus Single-Port Laparoscopic Surgery and conventional laparoscopic surgery: a prospective randomized comparative study of performance with novices in a dry laboratory.. 33. 2014
Benefit in regionalization of care for patients treated with nephrectomy: a Nationwide Inpatient Sample.. 32. 2014
Analysis of lymph node dissection in patients with ≥7-cm renal tumors.. 32. 2014
Non-squamous cell carcinoma of the penis: single-center, 15-year experience.. 32. 2013
Lower urinary tract symptoms improve with testosterone replacement therapy in men with late-onset hypogonadism: 5-year prospective, observational and longitudinal registry study.. 32. 2013
Assessment of the learning curves for photoselective vaporization of the prostate using GreenLight™ 180-Watt-XPS laser therapy: defining the intra-operative parameters within a prospective cohort.. 32. 2013
Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer.. 32. 2013
The hypothalamic-pituitary-gonadal axis and prostate cancer: implications for androgen deprivation therapy.. 32. 2013
Urodynamic characterization of lower urinary tract symptoms in men less than 40 years of age.. 32. 2013
Charlson score as a single pertinent criterion to select candidates for active surveillance among patients with small renal masses.. 32. 2013
The impact of smoking on pathologic response to neoadjuvant cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer.. 32. 2013
The surgical approach can be determined from the pathological specimen obtained after open or robot-assisted laparoscopic radical prostatectomy.. 32. 2013
Comparison of oncologic outcomes after radical prostatectomy in men diagnosed with prostate cancer with PSA levels below and above 4 ng/mL.. 32. 2013
Use of the Bulbocavernosus Reflex System in assessing voiding dysfunction.. 31. 2013
Functional outcomes following robotic prostatectomy using athermal, traction free risk-stratified grades of nerve sparing.. 31. 2013
Female gender is associated with higher risk of disease recurrence in patients with primary T1 high-grade urothelial carcinoma of the bladder.. 31. 2012
Effect of minimizing tension during robotic-assisted laparoscopic radical prostatectomy on urinary function recovery.. 31. 2012
Accurate risk assessment of patients with asymptomatic hematuria for the presence of bladder cancer.. 30. 2012
Disease-free survival as a surrogate for overall survival in upper tract urothelial carcinoma.. 31. 2012
Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy?. 30. 2012
Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.. 32. 2012
Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.. 30. 2011
Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group.. 30. 2011
Predicting prostate cancer many years before diagnosis: how and why?. 30. 2011
Multicenter validation of the prognostic value of patient age in patients treated with radical cystectomy.. 30. 2011
Does partial nephrectomy at an academic institution result in better outcomes?. 30. 2011
Association of tumor-associated trypsin inhibitor (TATI) expression with molecular markers, pathologic features and clinical outcomes of urothelial carcinoma of the urinary bladder.. 30. 2011
No overt influence of lymphadenectomy on cancer-specific survival in organ-confined versus locally advanced upper urinary tract urothelial carcinoma undergoing radical nephroureterectomy: a retrospective international, multi-institutional study.. 29. 2011
Preoperative radiographic parameters predict long-term renal impairment following partial nephrectomy.. 31. 2011
Chronological age is not an independent predictor of clinical outcomes after radical nephroureterectomy.. 29. 2011
Concomitant carcinoma in situ as an independent prognostic parameter for recurrence and survival in upper tract urothelial carcinoma: a multicenter analysis of 772 patients.. 29. 2011
Nerve-sparing technique and urinary control after robot-assisted laparoscopic prostatectomy.. 29. 2010
Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma.. 29. 2010
Application of new technology in bladder cancer diagnosis and treatment.. 27. 2009
From proficiency to expert, when does the learning curve for robotic-assisted prostatectomies plateau? The Columbia University experience.. 25. 2007
Gleason score and pretreatment prostate-specific antigen in survival among patients with stage D2 prostate cancer.. 22. 2004
Transforming growth factor-beta localization during mouse prostate morphogenesis and in prostatic growth abnormalities.. 13. 1995
Correction to: An evaluation of the federal adverse events reporting system data on adverse effects of 5‑alpha reductase inhibitors.. 39. 2021
Radiomics can predict tumour response in patients treated with Nivolumab for a metastatic renal cell carcinoma: an artificial intelligence concept. 2020
Intravesical therapy for bladder cancer in the pandemic of Covid-19. 2020
Response to: Greenlight^® users should move from photoselective vaporization to endoscopic enucleation in larger prostates : Benoit Peyronnet, Vincent Misrai, Tev Aho, Henry Woo, Thomas Herrmann, Fernando Gomez-Sancha. 2017
Focal laser ablation as clinical treatment of prostate cancer: report from a Delphi consensus project. 2019
ICUD guidelines for upper tract urothelial carcinoma: a state-of-the-art evidence-based guidance for clinical decisions regarding diagnosis, management and treatment.. 35. 2017
Urothelial carcinoma.. 29. 2011
Challenges in testicular cancer management.. 27. 2009
Association between SARS-CoV-2 infection and disease severity among prostate cancer patients on androgen deprivation therapy: a systematic review and meta-analysis. 2021
Incidence and outcome of salvage cystectomy after bladder sparing therapy for muscle invasive bladder cancer: a systematic review and meta-analysis. 2020
Making a case "against" focal therapy for intermediate-risk prostate cancer. 2020
Prognostic value of T1 substaging on oncological outcomes in patients with non-muscle-invasive bladder urothelial carcinoma: a systematic literature review and meta-analysis. 2019
Diagnostic performance of multidetector computed tomographic (MDCTU) in upper tract urothelial carcinoma (UTUC): a systematic review and meta-analysis. 2019
Impact of alcohol consumption on the risk of developing bladder cancer: a systematic review and meta-analysis. 2019
Oncologic outcomes after robot-assisted versus open radical cystectomy: a systematic review and meta-analysis. 2019
The effect of diet on BPH, LUTS and ED. 2018
Molecular markers in bladder cancer. 2018
The molecular limitations of biomarker research in bladder cancer. 2018
An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer. 2018
Molecularly-driven precision medicine for advanced bladder cancer. 2018
Current and future international patterns of care of neurogenic bladder after spinal cord injury. 2018
Is neutrophil-to-lymphocytes ratio a clinical relevant preoperative biomarker in upper tract urothelial carcinoma? A meta-analysis of 4385 patients. 2018
Patterns and predictors of recurrence after open radical cystectomy for bladder cancer: a comprehensive review of the literature. 2017
Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review. 2017
Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). 2016
Cytoreductive radical prostatectomy in metastatic prostate cancer: Does it really make sense? 2016
Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer. 2016
Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of low-risk upper tract urothelial carcinoma. 2016
Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review. 2016
Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease. 2016
Standardization of definitions in focal therapy of prostate cancer: report from a Delphi consensus project. 2016
Contemporary role of lymph node dissection at the time of radical nephroureterectomy for upper tract urothelial carcinoma. 2016
TOOKAD® Soluble focal therapy: pooled analysis of three phase II studies assessing the minimally invasive ablation of localized prostate cancer. 2015
Innovations in diagnostic imaging of localized prostate cancer. 2014
Outcomes of minimally invasive simple prostatectomy for benign prostatic hyperplasia: a systematic review and meta-analysis. 2014
Current controversies and challenges in robotic-assisted, laparoscopic, and open partial nephrectomies. 2014
The survival benefit of lymph node dissection at the time of removal of kidney, prostate and urothelial carcinomas: what is the evidence? 2013
Predictive tools for clinical decision-making and counseling of patients with upper tract urothelial carcinoma. 2012
Predictive factors of recurrence and survival of upper tract urothelial carcinomas. 2011
Impact of gender on bladder cancer incidence, staging, and prognosis. 2011
Outcomes assessment in men undergoing open retropubic radical prostatectomy, laparoscopic radical prostatectomy, and robotic-assisted radical prostatectomy. 2011
Health services research in urology. 2011
Salvage robotic assisted laparoscopic radical prostatectomy: indications and outcomes. 2010
Multi-modal treatment for metastatic renal cancer: the role of surgery. 2010
Good-risk-advanced germ cell tumors: historical perspective and current standards of care. 2009
Management of post-chemotherapy extra-retroperitoneal residual masses. 2009
Radical prostatectomy for high-risk prostate cancer. 2008
Survivin: a promising biomarker for detection and prognosis of bladder cancer. 2007
Retarded ejaculation. 2006
Staged based directed surveillance of invasive bladder cancer following radical cystectomy: valuable and effective? 2006
State-of-the-art management of metastatic disease at initial presentation or recurrence. 2006
Use of nomograms as predictive tools in bladder cancer. 2006
The evolution of photoselective vaporization prostatectomy (PVP): advancing the surgical treatment of benign prostatic hyperplasia. 2006
New drugs and new approaches for the treatment of metastatic urothelial cancer. 2002
Neo-adjuvant chemotherapy in invasive bladder cancer. 2001
Suicide gene therapy for prostate cancer using a replication-deficient adenovirus containing the herpesvirus thymidine kinase gene. 2000
Adrenocortical carcinoma. 1999
Diagnosis and treatment of primary aldosteronism. 1999
Applications of telomerase in urologic oncology. 1997
Molecular and immunopathology studies of oncogenes and tumor-suppressor genes in bladder cancer. 1997
Natural history of superficial bladder tumors: 10- to 20-year follow-up of treated patients. 1997
Molecular determinants of sexual differentiation. 1996
POU-domain gene expression during spermatogenesis. 1996
Genes involved in testicular development and function. 1995
Adjuvant chemotherapy following radical cystectomy. 1993
Artificial intelligence in medicine and male infertility. 1993
Paracrine factors and the regulation of spermatogenesis. 1993

VIVO Weill Cornell Medical College

World journal of urology Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)